The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational <scp>ZENSHIN</scp> study-Reference-Cited by-同舟云学术

The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study

Published:2022-11-10 Issue:5 Volume:12 Page:5265-5274
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Uemura Hiroji¹,Oya Mototsugu²,Kamoto Toshiyuki³,Sugimoto Mikio⁴,Shinozaki Kenta⁵,Morita Kiyomi⁵,Koto Ryo⁵,Takahashi Mai⁵,Nii Masahiro⁵,Shin Eisei⁵,Nonomura Norio⁶^ORCID

Affiliation:

1. Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama City Japan

2. Department of Urology Keio University School of Medicine Tokyo Japan

3. Department of Urology, Faculty of Medicine Miyazaki University Miyazaki Japan

4. Department of Urology, Faculty of Medicine Kagawa University Kagawa Japan

5. AstraZeneca K.K Osaka Japan

6. Department of Urology Osaka University Graduate School of Medicine Osaka Japan

Funder

AstraZeneca

Merck Sharp and Dohme

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5333

Reference42 articles.

1. International Agency for Research on Cancer.Estimated age‐standardized incidence and mortality rates (world) in 2020 worldwide males all ages.International Agency for Research on Cancer.2021.https://gco.iarc.fr/today/explore

2. Cancer Information Service National Cancer Center Japan (Ministry of Health Labour and Welfare National Cancer Registry) Cancer Registry and Statistics2020.https://ganjoho.jp/reg_stat/statistics/dl/index.html

3. Biology and natural history of prostate cancer and the role of chemoprevention

4. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors;Journal of the National Cancer Center;2024-09

2. Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real‐world setting of metastatic prostate cancer;BJU International;2024-07-10

3. A Systematic Review of Family History, Race/Ethnicity, and Genetic Risk on Prostate Cancer Detection and Outcomes: Considerations in PSA-based Screening;Urologic Oncology: Seminars and Original Investigations;2024-07

4. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis;Journal of Clinical Oncology;2024-05-10

5. Prostate cancer and liquid biopsies: Clinical applications and challenges;International Journal of Urology;2024-03-29